OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	124
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	110
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	98
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	94
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	85
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	71
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	67
CD47 expression in acute myeloid leukemia varies according to genotype	62
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	59
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	55
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	53
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	51
The first human acute myeloid leukemia genome ever fully sequenced	50
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	47
Acute myeloid leukemia at first relapse: approaching the precipice	46
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	46
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	45
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	45
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	45
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	45
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	44
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	43
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	42
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	40
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	39

Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	38
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	38
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	37
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	37
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	37
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	36
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	36
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	36
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	36
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	36